Cagrilintide and Tirzepatide: Stacking Amylin With a Dual Agonist — What the Data Actually Says
Searches for "cagrilintide dosage with tirzepatide" have surged as people look for ways to break through weight loss plateaus on tirzepatide (Mounjaro/Zepbound). The idea is straightforward: add cagrilintide, an amylin analog that works through entirely different receptors, to get additional appetite suppression that tirzepatide alone cannot provide.
This page covers what the published science actually says about combining these two drugs, the preclinical and clinical evidence, the safety concerns, and where retatrutide fits as a potentially simpler alternative.
What Each Drug Does
| Tirzepatide (Mounjaro/Zepbound) | Cagrilintide | |
|---|---|---|
| Drug class | Dual incretin agonist | Long-acting amylin analog |
| Receptors | GLP-1 + GIP | Amylin (AMY1R, AMY3R) + Calcitonin |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA status | Approved (Mounjaro 2022, Zepbound 2023) | Not approved (NDA filed as part of CagriSema, Dec 2025) |
| Dosing | Once weekly injection, 2.5-15 mg | Once weekly injection (studied at 0.3-4.5 mg in trials) |
| Max weight loss | -22.5% (SURMOUNT-1, 72 weeks) | -11.8% monotherapy (REDEFINE 1, 68 weeks) |
| Primary side effects | Nausea, diarrhea, constipation | Nausea, fatigue, injection site reactions |
The key point: these drugs target completely non-overlapping receptor systems. Tirzepatide works through incretin signaling (GLP-1 + GIP). Cagrilintide works through amylin signaling in the brainstem. This is why the combination concept exists — two independent appetite suppression pathways stacked together.
Why People Are Combining Them
The core motivation is appetite suppression plateau on tirzepatide.
A December 2025 case study published in Nature Medicine documented this phenomenon directly. Penn Medicine researchers implanted intracranial electrodes in a patient on tirzepatide and observed that reward-center (nucleus accumbens) activity went silent initially — the patient reported no food preoccupation. After five months at full dose, brain reward-center activity returned along with severe food cravings. The appetite-suppressing effect of tirzepatide had worn off while the patient was still on the drug.
Cagrilintide targets a completely different neural pathway (amylin receptors in the area postrema and brainstem satiety centers). The hypothesis is that adding amylin agonism can restore appetite suppression through a pathway that has not developed tolerance.
This is the same rationale behind Novo Nordisk's CagriSema: they combined cagrilintide with semaglutide (a GLP-1 agonist) and demonstrated that the combination produced 22.7% weight loss versus 16.1% for semaglutide alone in REDEFINE 1 — showing that amylin agonism meaningfully adds to incretin-based weight loss.
People stacking cagrilintide with tirzepatide are essentially trying to apply the CagriSema principle to a stronger base drug (tirzepatide instead of semaglutide).
Published Evidence for the Combination
Preclinical Data: ADA 2024
The only published data on the specific cagrilintide + tirzepatide combination comes from a preclinical study presented as a poster at the American Diabetes Association 2024 Scientific Sessions:
| Treatment | Weight Loss (12 days) | Notes |
|---|---|---|
| Cagrilintide 3 nmol/kg | -7.2% | Amylin agonist alone |
| Cagrilintide 10 nmol/kg | -9.6% | Higher dose |
| Tirzepatide 3 nmol/kg | -2.5% | Dual incretin alone |
| Tirzepatide 10 nmol/kg | -5.8% | Higher dose |
| Combination (3 + 3 nmol/kg) | -11.0% | Submaximal doses, synergistic effect (P<0.05) |
The combination at submaximal doses produced greater weight loss than either drug alone at maximal doses. It also showed superior ALT reduction and lower plasma triglycerides. The authors concluded this suggests a "potential opportunity for further clinical development."
However, this was a 12-day study in diet-induced obese rats — not humans.
CagriSema vs Tirzepatide: REDEFINE 4 (February 2026)
The closest human evidence comes from REDEFINE 4, Novo Nordisk's head-to-head trial comparing CagriSema (cagrilintide + semaglutide) against tirzepatide:
| CagriSema 2.4/2.4 mg | Tirzepatide 15 mg | |
|---|---|---|
| Weight loss (adherent) | -23.0% | -25.5% |
| Weight loss (all enrolled) | -20.2% | -23.6% |
| Primary endpoint | FAILED — did not demonstrate non-inferiority | Won |
| Duration | 84 weeks | 84 weeks |
| Participants | 809 total |
CagriSema failed to match tirzepatide on weight loss. This is significant for the stacking question: if Novo Nordisk's optimized combination of amylin + GLP-1 could not beat tirzepatide's dual GLP-1/GIP mechanism, it raises questions about whether adding cagrilintide to tirzepatide would produce meaningfully better results than tirzepatide alone at an optimized dose.
Eli Lilly's Answer: Eloralintide + Tirzepatide
Eli Lilly is developing its own amylin agonist, eloralintide, and is actively studying it in combination with tirzepatide in a Phase 2 trial (NCT06603571). This trial has nine treatment arms plus placebo, enrolling adults with obesity and type 2 diabetes, with a primary endpoint of weight change at 48 weeks.
Eloralintide monotherapy showed strong results in Phase 2:
| Dose | Weight Loss (48 weeks) |
|---|---|
| Eloralintide 1 mg | -9.5% |
| Eloralintide 3 mg | -12.4% |
| Eloralintide 6 mg | -17.6% |
| Eloralintide 9 mg | -20.1% |
| Placebo | -0.4% |
Lilly has stated it is "evaluating [eloralintide's] use as a complementary treatment to incretin therapy" — the pharmaceutical industry's version of amylin + incretin stacking. Results from the combination trial are not yet available.
Safety Concerns
No formal safety data exists for the cagrilintide + tirzepatide combination. The following concerns are inferred from each drug's individual safety profile:
Additive gastroparesis risk — Both cagrilintide (via amylin) and tirzepatide (via GLP-1) slow gastric emptying through different mechanisms. Combining them could cause severe gastroparesis. No clinical data quantifies this risk.
Excessive appetite suppression — Amylin agonism is a potent appetite suppressant. Combined with tirzepatide's dual mechanism, caloric intake could drop to levels that promote muscle loss, metabolic adaptation, and nutritional deficiencies.
Fatigue — Fatigue is the most consistently reported side effect from cagrilintide. This matches known amylin receptor biology — amylin agonism can affect energy levels through brainstem pathways.
No long-term safety data — Neither cagrilintide (as a standalone) nor eloralintide has multi-year safety data. The combination has zero human safety data.
Drug interaction unknowns — Tirzepatide and cagrilintide have never been studied together in a controlled setting. Pharmacokinetic interactions, if any, are unknown.
Where Retatrutide Fits
People stacking cagrilintide with tirzepatide are trying to achieve multi-pathway weight loss by combining two separate injections from two different companies. Retatrutide takes a fundamentally different approach: one molecule, three receptors.
| Cagrilintide + Tirzepatide (stacked) | Retatrutide | |
|---|---|---|
| Pathways | 4 (GLP-1 + GIP + Amylin + Calcitonin) | 3 (GLP-1 + GIP + Glucagon) |
| Injections | 2 separate injections per week | 1 injection per week |
| Clinical data | Zero human combination trials | Phase 3 (TRIUMPH program, 5,800+ participants) |
| Max weight loss | Unknown (no human data) | -28.7% at 68 weeks (TRIUMPH-4) |
| Unique mechanism | Amylin (appetite via brainstem) | Glucagon (increases energy expenditure) |
| FDA status | Neither approved as combination | Phase 3, approval expected 2027 |
Retatrutide does not hit the amylin pathway — it uses glucagon agonism instead, which increases energy expenditure and promotes fat oxidation. This is a different strategy: rather than adding a second appetite suppression pathway (amylin), retatrutide attacks the other side of the energy equation by increasing how many calories the body burns.
The result — 28.7% weight loss from a single, clinically-studied molecule — exceeds what CagriSema achieved (23.0%) against tirzepatide in the REDEFINE 4 head-to-head trial. It also does so without the complexity of managing two separate drugs, unknown interactions, and pH-sensitive reconstitution.
For a full comparison, see Retatrutide vs CagriSema.
Frequently Asked Questions
Can you take cagrilintide and tirzepatide together?
No clinical trial has studied this combination in humans. The only published data is a 12-day preclinical study in rats (ADA 2024) showing synergistic weight loss at submaximal doses. Eli Lilly is currently conducting a Phase 2 trial (NCT06603571) of its own amylin agonist (eloralintide) combined with tirzepatide, but results are not yet available. This combination should only be considered under direct physician supervision.
What is the cagrilintide dosage with tirzepatide?
No established dosing protocol exists because this combination has not been studied in clinical trials. Tirzepatide follows its standard FDA-approved titration (2.5 mg to 15 mg once weekly). Cagrilintide has been studied at doses from 0.3 mg to 4.5 mg once weekly in the CagriSema program. Any combination dosing would need to be determined by a physician.
Is cagrilintide the same as CagriSema?
No. Cagrilintide is one of the two components of CagriSema. CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (2.4 mg, an amylin analog) and semaglutide (2.4 mg, a GLP-1 agonist) in a single once-weekly injection. Cagrilintide alone is not FDA-approved for any indication.
Did CagriSema beat tirzepatide in the head-to-head trial?
No. In REDEFINE 4 (results announced February 23, 2026), CagriSema achieved 23.0% weight loss versus tirzepatide's 25.5% at 84 weeks. CagriSema failed to demonstrate non-inferiority to tirzepatide. Novo Nordisk is developing a higher-dose version (REDEFINE 11) expected in 2027.
Is retatrutide better than cagrilintide plus tirzepatide?
No direct comparison exists. Retatrutide achieved 28.7% weight loss at 68 weeks in TRIUMPH-4 using a single molecule targeting three receptors (GLP-1, GIP, glucagon). Cagrilintide + tirzepatide has never been studied together in humans. Retatrutide offers a simpler approach (one injection, one clinically-studied drug) but uses a different mechanism (glucagon instead of amylin). For a detailed comparison, see Retatrutide vs CagriSema.
What is eloralintide?
Eloralintide is Eli Lilly's investigational amylin receptor agonist (previously LY3841136). In Phase 2, it achieved up to 20.1% weight loss as monotherapy at 48 weeks. Lilly is currently studying it in combination with tirzepatide in a Phase 2 trial (NCT06603571) for adults with obesity and type 2 diabetes. Phase 3 monotherapy enrollment began in late 2025.
Sources
- Valdecantos, M.P., Rada, P., et al. (2024). Beneficial Effect of the Combination Therapy of Cagrilintide and Tirzepatide on Body Weight Loss in Obese Rats. Diabetes, 73(Supplement_1), 300-OR. DOI: 10.2337/db24-300-OR
- Aronne, L.J., et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2502081
- Novo Nordisk. (2026). CagriSema demonstrated 23% weight loss in open-label head-to-head REDEFINE 4 trial. Press release
- Eli Lilly. (2025). Eloralintide Phase 2 results. Press release
- ClinicalTrials.gov. Eloralintide + Tirzepatide Phase 2. NCT06603571
- Eli Lilly. (2025). TRIUMPH-4 results. Press release
- Shaker, A., et al. (2025). Intracranial recording of reward circuitry in a patient receiving tirzepatide. Nature Medicine. DOI: 10.1038/s41591-025-04035-5
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Cagrilintide is not FDA-approved. Combining cagrilintide with tirzepatide has never been studied in human clinical trials and carries unknown safety risks.
Do not combine medications without consulting a qualified healthcare provider. If you are experiencing a weight loss plateau on tirzepatide, speak with your prescribing physician about evidence-based options.
This site is not affiliated with Novo Nordisk, Eli Lilly, or any pharmaceutical manufacturer.
Sources
Related reading
Retatrutide vs CagriSema (Cagrilintide + Semaglutide): Triple Agonist vs Amylin + GLP-1 Combo
Cagrilintide vs retatrutide: triple agonist vs amylin + GLP-1 combo — 28.7% vs 22.7% weight loss, different receptors, and stacking considerations.
Retatrutide vs Mounjaro vs Ozempic
How the three generations of weight loss drugs compare — single, dual, and triple agonists.
Retatrutide vs Tirzepatide (Zepbound): Triple Agonist vs Dual Agonist
Retatrutide produces 28.7% weight loss (triple agonist) vs tirzepatide's 22.5% (dual agonist). A head-to-head trial is underway.